SION
NASDAQ HealthcareSionna Therapeutics, Inc. - Common Stock
Biotechnology
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
�� 市场数据
| 价格 | $43.54 |
|---|---|
| 成交量 | 506,681 |
| 市值 | 1.96B |
| RSI（14日） | 66.9 |
| 200日均线 | $33.09 |
| 50日均线 | $37.61 |
| 52周最高 | $46.46 |
| 52周最低 | $10.07 |
| Forward P/E | -16.87 |
| Price / Book | 6.35 |
🎯 投资策略评分
SION 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🐋 Institutional Whale (40/100) — 此策略 大盘、机构级别股票.
评分最低的策略： 🚀 Moon Shot (8/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 SION in your text
粘贴任何文章、记录或帖子 — 工具将提取 SION 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.